Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 15, 2026
Reporting period
Not applicable
Filed with the SEC
Sep 16, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-393274
Filed / recorded
Sep 16, 2026, 9:35 PM UTC
Added to OQRO
Oct 8, 2026, 12:30 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
AN2 Therapeutics, Inc.
Issuer CIK
1880438
Ticker
ANTX
Reporting person
Cameron C. Iii Trenor
Relationship
Officer
Officer title
Chief Medical Officer
Security
Stock Option (right to by)
Table
Derivative (Table II)
Transaction date
Sep 15, 2026
Transaction code
A
Shares / units
233,333
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
233,333
Ownership form
Direct
Amendment
No
Footnotes from the filing
The shares subject to the stock option vest as follows: 25% of the shares vest on August 24, 2027 and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.